Puma Biotechnology (NASDAQ:PBYI – Get Free Report) was upgraded by stock analysts at StockNews.com from a “hold” rating to a “buy” rating in a report released on Wednesday. Separately, HC Wainwright restated a “buy” rating and issued a $7.00 price objective on shares of Puma Biotechnology in a report on Monday, June 3rd. Read Our […]